10.10.19
Booth 4543
Gencor will introduce its newest ingredient AGEProst, an herbal extract of the plant Ageratum conyzoides, which has traditionally been used in the Caribbean for prostate and urinary problems.
AGEprost is a 5-a-reductase inhibitor and has shown to be able to relax muscles around the urethra and smooth muscles of the neck of the bladder helping relieve urinary retention and frequency. It can also block conversion of testosterone to DHT with subsequent reduction in prostate size improving urine flow.
“As men age, prostate health becomes top of mind, and this unique extract has been clinically tested and shown to reduce symptom severity according to study applicants in the International Prostate Symptom Score (IPSS),” said R.V. Venkatesh, Managing Director at Gencor. “We are thrilled to add yet another unique and clinically validated ingredient to our portfolio.”
The 12-week double-blind, randomized, placebo-controlled study was conducted on 109 men aged 41-76 years old to study and assess the efficacy and safety of Ageratum conyzoides. In the active group, there was a steady reduction in the symptom severity for all questions in the IPSS, and a decrease in both daytime and nighttime frequency with significant reduction in total urinary frequency.
“We expect AGEprost to be a strong contender in the men’s health marketplace due to its significant positive results shown from the clinical studies,” said Chase Shryoc, VP of Business Development at Gencor. “With several in-vitro and in-vivo studies, AGEprost is a well-researched, self-affirmed GRAS status ingredient with an excellent safety profile.”
Gencor will introduce its newest ingredient AGEProst, an herbal extract of the plant Ageratum conyzoides, which has traditionally been used in the Caribbean for prostate and urinary problems.
AGEprost is a 5-a-reductase inhibitor and has shown to be able to relax muscles around the urethra and smooth muscles of the neck of the bladder helping relieve urinary retention and frequency. It can also block conversion of testosterone to DHT with subsequent reduction in prostate size improving urine flow.
“As men age, prostate health becomes top of mind, and this unique extract has been clinically tested and shown to reduce symptom severity according to study applicants in the International Prostate Symptom Score (IPSS),” said R.V. Venkatesh, Managing Director at Gencor. “We are thrilled to add yet another unique and clinically validated ingredient to our portfolio.”
The 12-week double-blind, randomized, placebo-controlled study was conducted on 109 men aged 41-76 years old to study and assess the efficacy and safety of Ageratum conyzoides. In the active group, there was a steady reduction in the symptom severity for all questions in the IPSS, and a decrease in both daytime and nighttime frequency with significant reduction in total urinary frequency.
“We expect AGEprost to be a strong contender in the men’s health marketplace due to its significant positive results shown from the clinical studies,” said Chase Shryoc, VP of Business Development at Gencor. “With several in-vitro and in-vivo studies, AGEprost is a well-researched, self-affirmed GRAS status ingredient with an excellent safety profile.”
